Report cover image

Global Ophthalmic AAV Gene Therapy Market Growth (Status and Outlook) 2026-2032

Published Jan 14, 2026
Length 76 Pages
SKU # LPI20716205

Description

The global Ophthalmic AAV Gene Therapy market size is predicted to grow from US$ 89.28 million in 2025 to US$ 591 million in 2032; it is expected to grow at a CAGR of 31.6% from 2026 to 2032.

Ophthalmic AAV gene therapy is a gene - treatment method that uses adeno - associated virus (AAV) as a vector to deliver therapeutic genes to specific eye cells for the treatment of ophthalmic diseases. It's the application of gene therapy in the field of ophthalmology, providing new treatment ideas and means for many intractable ophthalmic diseases.

United States market for Ophthalmic AAV Gene Therapy is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.

China market for Ophthalmic AAV Gene Therapy is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.

Europe market for Ophthalmic AAV Gene Therapy is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.

Global key Ophthalmic AAV Gene Therapy players cover Spark/Roche (Luxturna), GenSight Biologics (Pipeline), etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.

LPI (LP Information)' newest research report, the “Ophthalmic AAV Gene Therapy Industry Forecast” looks at past sales and reviews total world Ophthalmic AAV Gene Therapy sales in 2025, providing a comprehensive analysis by region and market sector of projected Ophthalmic AAV Gene Therapy sales for 2026 through 2032. With Ophthalmic AAV Gene Therapy sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Ophthalmic AAV Gene Therapy industry.

This Insight Report provides a comprehensive analysis of the global Ophthalmic AAV Gene Therapy landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Ophthalmic AAV Gene Therapy portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Ophthalmic AAV Gene Therapy market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Ophthalmic AAV Gene Therapy and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Ophthalmic AAV Gene Therapy.

This report presents a comprehensive overview, market shares, and growth opportunities of Ophthalmic AAV Gene Therapy market by product type, application, key players and key regions and countries.

Segmentation by Type:
Subretinal Injection
Intravitreous Injection

Segmentation by Application:
Retinopathy
Optic Atrophy

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Spark/Roche (Luxturna)
GenSight Biologics (Pipeline)

Please note: The report will take approximately 2 business days to prepare and deliver.

Table of Contents

76 Pages
*This is a tentative TOC and the final deliverable is subject to change.*
1 Scope of the Report
2 Executive Summary
3 Ophthalmic AAV Gene Therapy Market Size by Player
4 Ophthalmic AAV Gene Therapy by Region
5 Americas
6 APAC
7 Europe
8 Middle East & Africa
9 Market Drivers, Challenges and Trends
10 Global Ophthalmic AAV Gene Therapy Market Forecast
11 Key Players Analysis
12 Research Findings and Conclusion
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.